

REMARKS

As indicated in the Notice of Allowance, claims 77, 83, 84, and 114-117 have been allowed. Claims 1-76, 78-82, 85-113, and 118 have been canceled.

By the foregoing amendments, claim 77, as set forth in the Examiner's Amendment, has been amended to recite "wherein an increased d level of said RNA..." and to delete an extraneous comma and space at the end of this claim.


Claims 83 and 117 have been amended to recite the transition phrase "comprises" rather than "is comprising." The claim amendments therefore address issues of a grammatical and/or typographical nature, or otherwise conform the claims better to accepted claim drafting practice.

The amendments introduce no new matter, and their entry under 37 C.F.R. § 1.312 is respectfully requested.

Please continue to direct all correspondence in this application to Novartis Vaccines and Diagnostics, Inc. at the address provided for Customer No. 27476.

Respectfully submitted,  
BANNER & WITCOFF, LTD.

Date: April 5, 2010

By:   
Benjamin C. Spehlmann  
Reg. No. 45,649

Customer No. 22907